Curis, Inc. (CRIS)

Nasdaq: CRIS · Biological Products, (No Diagnostic Substances) · Lexington, MA · filing with the SEC since 2000

Full chart Alerts Compare

Grade4.1

◀ Past 3.4● Present 4.1▶ Future 4.5

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$9.4M-13.4%

Net income-$7.6M+82.5%

Earnings per share$-0.58+91.6%

Operating cash flow-$27.2M+31.2%

Cash$5.1M-74.7%

Debtn/a

Shareholders’ equity$5.5M+191.1%

Shares, diluted13.2M+108.7%

Return on equity-138.8%

The recordfrom its filings

Filings in 202662

Newest filingNov 10 · SCHEDULE 13G/A

Annual reportMar 24, 2026

Quarterly reportAug 14, 2026

Next report due10-Q by Nov 14

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted142

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Jun 2026Revenue $4.3MNet income -$21.2MCash from operations -$30.6Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

16171819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 6, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Nov 2, 2026 · SEC EDGAR · Form DEF 14A

Proxy statement

Open the filing on sec.gov

Oct 23, 2026 · SEC EDGAR · Form PRE 14A

Preliminary proxy statement

Open the filing on sec.gov

Oct 19, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Aug 14, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form 424B4

Offering prospectus

Open the filing on sec.gov

Aug 12, 2026 · SEC EDGAR · Form EFFECT

Registration effective

Open the filing on sec.gov

Aug 10, 2026 · SEC EDGAR · Form S-1

Listing registration

Open the filing on sec.gov

Jul 30, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Curis, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Lexington, MA.

Newest on the record

Large holder update, amended on Nov 10. Before it, current report on Nov 6.

What is due next

The 10-Q for the period to Sep 30, 2026, due by Nov 14, 2026.

About CRIS

Curis, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Lexington, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $9.4 million and a loss of $7.6 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersLexington, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2000

Fiscal year endsDec 31

SEC number (CIK)1108205

Peers on fileOTLK, PLUR, ENTX, INKT

Who runs it

Financial performance

In fiscal 2025 Curis’s revenue was $9.44 million, down 13.4% from $10.91 million the year before. It made a net loss of $7.58 million.

Annual report, filed Mar 24, 2026.

Financial statements

The grade

Curis grades 4.1 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past3.4

● Present4.1

▶ Future4.5

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton CRIS · research, not advice